These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22398597)

  • 81. Resolution of Intestinal Histopathology Changes in Cystic Fibrosis after Treatment with Ivacaftor.
    Safe M; Gifford AJ; Jaffe A; Ooi CY
    Ann Am Thorac Soc; 2016 Feb; 13(2):297-8. PubMed ID: 26848606
    [No Abstract]   [Full Text] [Related]  

  • 82. Triple CFTR Modulator Therapy for Cystic Fibrosis.
    Holguin F
    N Engl J Med; 2018 Oct; 379(17):1671-1672. PubMed ID: 30334694
    [No Abstract]   [Full Text] [Related]  

  • 83. Drug combination that corrects deficient protein in cystic fibrosis improves lung function.
    Mayor S
    BMJ; 2015 May; 350():h2689. PubMed ID: 25990552
    [No Abstract]   [Full Text] [Related]  

  • 84. A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants.
    Wainwright CE
    Am J Respir Crit Care Med; 2022 Nov; 206(10):1193-1195. PubMed ID: 35856818
    [No Abstract]   [Full Text] [Related]  

  • 85. SIMPLIFYing cystic fibrosis treatment in a post-modulator era.
    Yang C
    Lancet Respir Med; 2023 Apr; 11(4):299-300. PubMed ID: 36463912
    [No Abstract]   [Full Text] [Related]  

  • 86.
    Yeh HI; Hwang TC
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 35210304
    [No Abstract]   [Full Text] [Related]  

  • 87. The ageing of Cystic Fibrosis patients with new modulators: current gaps and challenges.
    Felipe Montiel A; Álvarez Fernández A; Traversi L; Polverino E
    Expert Rev Respir Med; 2023 Dec; 17(12):1091-1094. PubMed ID: 38347811
    [No Abstract]   [Full Text] [Related]  

  • 88. A little CFTR can change a lot: slowing cystic fibrosis progression.
    Rowe SM
    Lancet Respir Med; 2017 Feb; 5(2):86-87. PubMed ID: 28011036
    [No Abstract]   [Full Text] [Related]  

  • 89. [Mucoviscidosis, a challenging medical problem].
    Esedov EM; Gadzhimirzaev GA; Akhmedova FD; Muradova VR; Gadzhimirzaeva RG; Medzhidova RA; Abasova AS
    Vestn Otorinolaringol; 2016; 81(5):15-18. PubMed ID: 27876728
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Pricing for orphan drugs: will the market bear what society cannot?
    O'Sullivan BP; Orenstein DM; Milla CE
    JAMA; 2013 Oct; 310(13):1343-4. PubMed ID: 24084916
    [No Abstract]   [Full Text] [Related]  

  • 91. COUNTERPOINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? No.
    Thursfield RM; Shafi N; Davies JC
    Chest; 2022 Jan; 161(1):21-24. PubMed ID: 35000702
    [No Abstract]   [Full Text] [Related]  

  • 92. The Future of Highly Effective Modulator Therapy in Cystic Fibrosis.
    Daines CL; Morgan WJ
    Am J Respir Crit Care Med; 2021 Jun; 203(12):1453-1455. PubMed ID: 33901406
    [No Abstract]   [Full Text] [Related]  

  • 93. Response.
    Durmowicz AG; Witzmann KA; Rosebraugh CJ; Chowdhury BA
    Chest; 2013 Oct; 144(4):1418-1419. PubMed ID: 24081359
    [No Abstract]   [Full Text] [Related]  

  • 94. Understanding the relationship between sweat chloride and lung function in cystic fibrosis.
    Heltshe SL; Mayer-Hamblett N; Rowe SM
    Chest; 2013 Oct; 144(4):1418. PubMed ID: 24081360
    [No Abstract]   [Full Text] [Related]  

  • 95. Adherence to Ivacaftor is suboptimal.
    Abbott J; Bilton D
    J Cyst Fibros; 2015 Sep; 14(5):547-8. PubMed ID: 26303992
    [No Abstract]   [Full Text] [Related]  

  • 96. Cystic fibrosis: a review of pathophysiology and current treatment recommendations.
    Peters S
    S D Med; 2014 Apr; 67(4):148-51, 153. PubMed ID: 24791377
    [No Abstract]   [Full Text] [Related]  

  • 97. In response to "who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies".
    McGarry ME; McColley SA; Taylor-Cousar J
    Respir Med; 2022 Oct; 202():106953. PubMed ID: 36049345
    [No Abstract]   [Full Text] [Related]  

  • 98. 50 years ago in The Journal of Pediatrics: The use of N-acetylcysteine in the treatment of cystic fibrosis.
    Cantu-Gonzalez G
    J Pediatr; 2014 Oct; 165(4):721. PubMed ID: 25256050
    [No Abstract]   [Full Text] [Related]  

  • 99. Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing.
    Hoppe JE; Zemanick ET; Martiniano SL
    Am J Respir Crit Care Med; 2022 Dec; 206(11):1308-1310. PubMed ID: 35947636
    [No Abstract]   [Full Text] [Related]  

  • 100. Long-term effect of CFTR modulator therapy on airway nitric oxide.
    Grasemann H; Klingel M; Avolio J; Prentice C; Gonska T; Tullis E; Ratjen F
    Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31601715
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.